Last reviewed · How we verify
Entecavir+Carvedilol+ Fuzheng Huayu
Entecavir+Carvedilol+ Fuzheng Huayu is a Combination therapy: nucleoside reverse transcriptase inhibitor + beta-blocker + herbal medicine Small molecule drug developed by ShuGuang Hospital. It is currently FDA-approved for Chronic hepatitis B with cirrhosis or advanced fibrosis, Hepatitis B-related portal hypertension.
This combination therapy targets hepatitis B virus replication (entecavir), reduces cardiac workload and improves heart function (carvedilol), and enhances liver fibrosis resolution through traditional Chinese medicine principles (Fuzheng Huayu).
This combination therapy targets hepatitis B virus replication (entecavir), reduces cardiac workload and improves heart function (carvedilol), and enhances liver fibrosis resolution through traditional Chinese medicine principles (Fuzheng Huayu). Used for Chronic hepatitis B with cirrhosis or advanced fibrosis, Hepatitis B-related portal hypertension.
At a glance
| Generic name | Entecavir+Carvedilol+ Fuzheng Huayu |
|---|---|
| Sponsor | ShuGuang Hospital |
| Drug class | Combination therapy: nucleoside reverse transcriptase inhibitor + beta-blocker + herbal medicine |
| Modality | Small molecule |
| Therapeutic area | Hepatology; Infectious Disease; Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Entecavir is a nucleoside reverse transcriptase inhibitor that suppresses hepatitis B virus replication. Carvedilol is a non-selective beta-blocker with alpha-blocking properties that reduces portal hypertension and cardiac stress. Fuzheng Huayu is a traditional Chinese medicine formula designed to promote liver regeneration and reduce hepatic fibrosis through immunomodulation and anti-inflammatory mechanisms.
Approved indications
- Chronic hepatitis B with cirrhosis or advanced fibrosis
- Hepatitis B-related portal hypertension
Common side effects
- Fatigue
- Dizziness
- Bradycardia
- Lactic acidosis (entecavir-related)
- Gastrointestinal disturbance
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Entecavir+Carvedilol+ Fuzheng Huayu CI brief — competitive landscape report
- Entecavir+Carvedilol+ Fuzheng Huayu updates RSS · CI watch RSS
- ShuGuang Hospital portfolio CI
Frequently asked questions about Entecavir+Carvedilol+ Fuzheng Huayu
What is Entecavir+Carvedilol+ Fuzheng Huayu?
How does Entecavir+Carvedilol+ Fuzheng Huayu work?
What is Entecavir+Carvedilol+ Fuzheng Huayu used for?
Who makes Entecavir+Carvedilol+ Fuzheng Huayu?
What drug class is Entecavir+Carvedilol+ Fuzheng Huayu in?
What development phase is Entecavir+Carvedilol+ Fuzheng Huayu in?
What are the side effects of Entecavir+Carvedilol+ Fuzheng Huayu?
Related
- Drug class: All Combination therapy: nucleoside reverse transcriptase inhibitor + beta-blocker + herbal medicine drugs
- Manufacturer: ShuGuang Hospital — full pipeline
- Therapeutic area: All drugs in Hepatology; Infectious Disease; Cardiovascular
- Indication: Drugs for Chronic hepatitis B with cirrhosis or advanced fibrosis
- Indication: Drugs for Hepatitis B-related portal hypertension
- Compare: Entecavir+Carvedilol+ Fuzheng Huayu vs similar drugs
- Pricing: Entecavir+Carvedilol+ Fuzheng Huayu cost, discount & access